Humate-P Approved For Treatment Of Bleeding Episodes In Von Willebrand Disease
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Humate-P Approved For Treatment Of Bleeding Episodes In Von Willebrand Disease

KING OF PRUSSIA, PA -- June 4, 1999 -- The United States Food and Drug Administration has approved Centeon L.L.C.'s Humate-P(R) (antihemophilic factor/von Willebrand factor complex [human], dried, pasteurised) for the treatment of bleeding due to von Willebrand disease (vWD).

Humate-P will also continue to be sold in the U.S. for the treatment of classical hemophilia (hemophilia A). Humate-P(R) will now be labelled with Factor VIII and Ristocetin Cofactor activity.

Humate-P is indicated in adult patients for the treatment and prevention of bleeding in hemophilia A (classical hemophilia) and in adult and pediatric patients for treatment of spontaneous and trauma-induced bleeding episodes in severe von Willebrand disease, and in mild and moderate von Willebrand disease where use of desmopressin is known or suspected to be inadequate.

Von Willebrand disease is the most common hereditary bleeding disorder, with a prevalence as high as one percent of the general population. Humate-P is the only von Willebrand factor replacement product on the U.S. market that is indicated for use with vWD patients.

The ability of Humate-P to assist in the control of bleeding in patients with vWD was demonstrated by data from a pivotal study involving 46 vWD patients. Of the bleeding episodes experienced by adult patients who received Humate-P, at least 95 percent were reported to have an excellent or good response to Humate-P. Of the bleeding episodes in children with vWD who were treated with Humate-P, at least 93 percent were reported to have an excellent or good response to the treatment.

In clinical trials with 97 patients, Humate-P was well tolerated with the following common side effects that included allergic reaction, uticaria, chest tightness, rash, pruritus and edema. Anaphylactic reactions may occur in very rare instances. As with all plasma-derived products, the risk of transmission of infectious agents, including viruses, cannot be completely eliminated.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities